Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 17 2020 - 06:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 16, 2020
________________
NOVO NORDISK A/S
(Exact name of Registrant as
specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark
whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
|
Form 20-F
[X] |
Form 40-F
[ ] |
Indicate by check mark
whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked,
indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share
repurchase programme
Bagsværd, Denmark,
16 November 2020 – On 3 November 2020, Novo Nordisk
initiated a share repurchase programme in accordance with Article 5
of Regulation No 596/2014 of the European Parliament and Council of
16 April 2014 (MAR) and the Commission Delegated Regulation (EU)
2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This
programme is part of the overall share repurchase programme of up
to DKK 17 billion to be executed during a 12- month period
beginning 5 February 2020.
Under the programme initiated 3 November 2020, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.7 billion in the
period from 4 November 2020 to 1 February 2021.
Since the announcement of the programme, the following transactions
have been made:
|
|
Number
of
B shares |
Average
purchase price |
Transaction
value, DKK |
| Accumulated,
last announcement |
330,000 |
|
146,988,294 |
| 9
November 2020 |
115,000 |
434.89 |
50,012,794 |
| 10
November 2020 |
115,000 |
424.34 |
48,798,527 |
| 11
November 2020 |
115,000 |
428.30 |
49,254,439 |
| 12
November 2020 |
115,000 |
431.00 |
49,565,155 |
|
13
November 2020 |
115,000 |
429.22 |
49,360,588 |
|
Accumulated
under the programme |
905,000 |
|
393,979,797 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have
resulted in a net transfer from Novo Nordisk of 13,210 B shares in
the period from 9 November 2020 to 13 November 2020. The shares in
these transactions were not part of the Safe Harbour repurchase
programme.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of
34,428,659 B shares of DKK 0.20 as treasury shares, corresponding
to 1.5% of the share capital. The total amount of A and B shares in
the company is 2,350,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK
17 billion during a 12- month period beginning 5 February 2020. As
of 13 November 2020, Novo Nordisk has since 5 February 2020
repurchased a total of 34,490,522 B shares at an average share
price of DKK 424.97 per B share equal to a transaction value of DKK
14,657,409,268.
Novo Nordisk is a leading global
healthcare company, founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat diabetes and other serious
chronic diseases such as obesity and rare blood and endocrine
disorders. We do so by pioneering scientific breakthroughs,
expanding access to our medicines and working to prevent and
ultimately cure disease. Novo Nordisk employs about 44,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Twitter, LinkedIn,
YouTube.
Further information
| Media: |
|
|
| Anne
Margrethe Hauge |
+45
4442 3450 |
amhg@novonordisk.com |
| Ken
Inchausti (US) |
+1 609
240 9429 |
kiau@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel
Muusmann Bohsen |
+45
3075 2175 |
dabo@novonordisk.com |
| Valdemar Borum Svarrer |
+45
3079 0301 |
jvls@novonordisk.com |
| Ann
Søndermølle Rendbæk |
+45
3075 2253 |
arnd@novonordisk.com |
| Mark
Joseph Root |
+45
3079 4211 |
mjhr@novonordisk.com |
| Kristoffer Due Berg (US) |
+1 609
235 2989 |
krdb@novonordisk.com |
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
| |
|
Company announcement No 70 / 2020 |
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
| Date: November
16, 2020 |
NOVO
NORDISK A/S
Lars Fruergaard Jørgensen
Chief
Executive Officer
|
